We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Galapagos Reports Topline Data From Osteoarthritis Study
Read MoreHide Full Article
Galapagos NV (GLPG - Free Report) announced positive top-line data from phase Ib study evaluating its osteoarthritis (“OA”) candidate, GLPG1972. The candidate reduced the level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in its highest dosage.
Shares of the company have risen 43.1% in the past year, outperforming the industry’s decline of 1.7% in that period.
The phase Ib study evaluated three doses of GLPG1972 versus placebo over a period of four weeks. GLPG1972 reduced level of ARGS neoepitope by 38.4%, 44.9% & 50.4% for low, medium and high dose, respectively, compared to 3.6% for placebo.
GLPG1972 works by targeting ADAMTS-5, a cartilage degrading enzyme.
Meanwhile, Galapagos is working on designing the phase II program to further evaluate the candidate in OA. The study is expected to start by the end of this year.
Apart from GLPG1972, Galapagos is also developing another candidate, filgotinib in Sjogren's syndrome, non-infectious uveitis, ankylosing spondylitis, and psoriatic arthritis. The company has a global collaboration with Gilead Sciences, Inc. (GILD - Free Report) for the development and commercialization of filgotinib in inflammatory indications.
Moreover, Galapagos is developing GLPG2222 in cystic fibrosis (“CF”) patients who are on long-term stable treatment with Vertex Pharmaceuticals Incorporated’s (VRTX - Free Report) CF drug, Kalydeco. In November last year, Galapagos announced positive top-line data from a phase II study, demonstrating an improvement of 2.2% in lung function compared to baseline.
The company has three CF candidate including GLPG2222, which are being developed in partnership with AbbVie Inc. (ABBV - Free Report) .
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Galapagos Reports Topline Data From Osteoarthritis Study
Galapagos NV (GLPG - Free Report) announced positive top-line data from phase Ib study evaluating its osteoarthritis (“OA”) candidate, GLPG1972. The candidate reduced the level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in its highest dosage.
Shares of the company have risen 43.1% in the past year, outperforming the industry’s decline of 1.7% in that period.
The phase Ib study evaluated three doses of GLPG1972 versus placebo over a period of four weeks. GLPG1972 reduced level of ARGS neoepitope by 38.4%, 44.9% & 50.4% for low, medium and high dose, respectively, compared to 3.6% for placebo.
GLPG1972 works by targeting ADAMTS-5, a cartilage degrading enzyme.
Meanwhile, Galapagos is working on designing the phase II program to further evaluate the candidate in OA. The study is expected to start by the end of this year.
Apart from GLPG1972, Galapagos is also developing another candidate, filgotinib in Sjogren's syndrome, non-infectious uveitis, ankylosing spondylitis, and psoriatic arthritis. The company has a global collaboration with Gilead Sciences, Inc. (GILD - Free Report) for the development and commercialization of filgotinib in inflammatory indications.
Moreover, Galapagos is developing GLPG2222 in cystic fibrosis (“CF”) patients who are on long-term stable treatment with Vertex Pharmaceuticals Incorporated’s (VRTX - Free Report) CF drug, Kalydeco. In November last year, Galapagos announced positive top-line data from a phase II study, demonstrating an improvement of 2.2% in lung function compared to baseline.
The company has three CF candidate including GLPG2222, which are being developed in partnership with AbbVie Inc. (ABBV - Free Report) .
Galapagos NV Price
Galapagos NV Price | Galapagos NV Quote
Galapagos carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>